Peptide Glow Journal

Peptides for Hair Growth in Women: Who Was Actually in the Trials

Every placebo-controlled trial of a topical hair peptide we could open enrolled men, or did not report how many women it enrolled. Here is the census, and the one study that did measure women's hair.

Fiona G · Edited by Caroline S · Published 2026-09-10

Illustration: A magnified single strand of dark hair on a warm beige ceramic tile, lit by natural light.
Illustration

The hair-peptide category is marketed heavily to women. The trials behind it were mostly run in men — and one of the largest never says how many women it enrolled at all.

This page is a census rather than a verdict. For each placebo-controlled study of a defined hair peptide, we opened the published record and wrote down who was in it. The result is short enough to state in a sentence: of the placebo-controlled topical trials we could open, three enrolled men only and the fourth does not report the sex of its 30 volunteers. The evidence tier for each ingredient — how big, how funded, how measured — is on our peptides for hair growth page. This page asks a narrower question that the tier does not answer.

The census

Study Who was enrolled Duration What it measured
GPIGS pentapeptide, Shiseido authors (J Cosmet Dermatol 2016) 22 Japanese men with androgenetic alopecia 4 months Proportion of hairs ≥60 μm
Capixyl, Lucas Meyer R&D (J Cosmet Sci 2013) 30 volunteers "with recessing hair" — sex not reported 4 months Anagen/telogen ratio by TrichoScan
Procapil, Sederma dossier (2004, unpublished) 35 men 4 months Anagen/telogen ratio, growth rate
GHK + 5-aminolevulinic acid complex (Ann Dermatol 2016) 45 men 6 months Hair count and diameter
Sphinganine, Evonik and DermaTronnier (Clin Cosmet Investig Dermatol 2016) Males and females with diffuse hair reduction — Hair loss; the published in vivo efficacy statement names males

The last row is the closest the topical literature comes to a mixed-sex study, and it carries two complications. The first is that its published result for hair loss is stated for males. The second is a naming problem that runs through this whole category: sphinganine is a sphingolipid, not a peptide. The peptide in that paper is HBD2, an antimicrobial peptide the scalp produces itself, which the authors measured as a marker of scalp health.

What the database returns for women

Searching PubMed on 2026-09-10 for peptide[tiab] AND androgenetic alopecia[tiab] AND (female[tiab] OR women[tiab]) returns three records. We opened all three:

None of the three is a trial of a hair peptide in women. The same database returns 170 records for minoxidil in female pattern hair loss. The gap between 170 and zero is the honest summary of where the evidence sits for the two options a woman actually encounters on a shelf.

The one female dataset, and it is oral

There is a substantial trial in women with a measured hair outcome, and it is easy to miss because it is filed under cellulite.

In a randomised, placebo-controlled study published in J Med Food in 2026, 114 women aged 20 to 50 with thigh cellulite and self-reported hair thinning took a low-molecular-weight fish collagen peptide — 1,000 mg a day in the trial protocol — or placebo for 24 weeks. Cellulite severity, skin roughness and elasticity improved against placebo at weeks 12 and 24, and hair diameter increased significantly at week 24, with more participants in the treated group showing measurable thickening. The authors are at NEWTREE, the company producing the ingredient, and the paper carries a declaration of no competing financial interests.

Three things are worth stating plainly about that study before it is used as an answer. It is oral supplementation, not a scalp product. Its hair endpoint is shaft diameter, not the number of hairs — a different outcome from regrowth, and one we take apart on peptides for hair thickness. And the participants were selected for cellulite, with self-reported thinning as a secondary characteristic, so the population is not the one a hair clinic would recruit. Our collagen peptides for hair and skin page sets out the rest of the oral-collagen evidence, including its weaknesses.

Why the absence is not a verdict

The topical peptides in the census were not tested in women and failed. They were not tested in women. Those are different statements, and the second one is what the record supports.

There is a structural reason the trials look this way. Male pattern hair loss recedes along a standardised, photographable pattern, which lets a four-month cosmetic study grade before-and-after images against the Norwood scale — the GPIGS trial did exactly that, with blinded reviewers. Female pattern hair loss is diffuse, and the commonest female complaint, telogen effluvium, frequently resolves without any treatment, which means an uncontrolled study in women will nearly always look successful. Choosing men makes a small cosmetic trial cheaper and its result cleaner. It also means the resulting number was never measured in the audience the product is sold to.

A biological argument runs the other way and deserves the same scepticism. Two of the ingredients here — the red-clover extract combined with the peptide in Capixyl, and the sphingolipid above — are proposed to work by inhibiting 5-alpha-reductase, the enzyme that makes dihydrotestosterone. That mechanism is the male-pattern story, and in women the role of androgens in diffuse thinning is more variable. An ingredient whose proposed mechanism is anti-androgenic has, if anything, a weaker prior in a population whose hair loss is often not androgen-driven. We treat that as a reason to want the trial, not as a prediction of its result. The mechanism claims themselves are examined on peptides for hair growth in men.

What the labelled drugs say by comparison

The two treatments with regulatory approval are labelled differently by sex, and that difference is a useful yardstick for how much sex-specific evidence a hair claim can carry.

Finasteride's label for male pattern hair loss states that it is not indicated for women, and warns that women who are or may become pregnant should not handle crushed or broken tablets. Over-the-counter minoxidil is sold in separate men's and women's presentations with their own directions and their own warnings; the women's labelling directs a user who sees no result after six months to stop and ask a doctor, and lists hair loss associated with childbirth among the situations in which the product should not be used without medical advice.

Cosmetic peptides carry none of this, because cosmetic ingredients are not required to. That is a regulatory fact rather than a criticism — but it does mean the sex-specific information a shopper gets from a drug label has no equivalent on a peptide serum carton.

Where this leaves the question

For a woman reading ingredient lists, the published record supports a narrow set of statements. No topical hair peptide has been shown in a placebo-controlled trial in women to do anything. One oral collagen peptide increased hair shaft diameter in 114 women over 24 weeks in a manufacturer-authored trial whose main subject was cellulite. The two approved drugs have hundreds of studies between them, including a Cochrane review of minoxidil that pooled 5,290 participants.

Anything stronger than that is being supplied by the marketing rather than by the studies. Shedding that is sudden, patchy, or accompanied by an inflamed scalp is a reason to see a dermatologist rather than to buy a serum; the American Academy of Dermatology puts normal daily shedding at 50 to 100 hairs and recommends a clinician to distinguish shedding from true loss.

Sources

Frequently asked questions

Do peptides work for hair growth in women?

No placebo-controlled trial of a topical hair peptide in women has been published that we could locate. The four placebo-controlled topical studies we opened enrolled 22, 35 and 45 men respectively, and the fourth reported 30 volunteers without stating the sex split. A database search for peptide research in women with androgenetic alopecia returns three records and none is a trial of a hair peptide. That is an absence of evidence rather than evidence of absence, but it is what the published record contains.

Why do hair-peptide trials enrol men?

Androgenetic alopecia in men is a visually gradable, slowly progressing condition with a standardised photographic scale, which makes a four-month cosmetic trial easier to run and easier to show a change in. Female pattern hair loss is diffuse rather than patterned, and the commonest female shedding complaint, telogen effluvium, often resolves on its own, which makes any treated group look effective. Neither reason is a finding about whether the ingredients work in women.

Is there any peptide with evidence in women's hair?

The one substantial dataset is an oral collagen peptide. In a randomised placebo-controlled trial of 114 women aged 20 to 50 who reported hair thinning, hair diameter increased significantly by week 24 (J Med Food 2026). The trial's primary subject was thigh cellulite, hair diameter was one of several endpoints, and the authors work for the company that makes the ingredient. It is oral supplementation measured on shaft calibre, not a topical peptide measured on regrowth.

What about postpartum shedding and peptides?

Four PubMed records join peptides with pregnancy or postpartum hair, and none of them tests a cosmetic hair peptide for postpartum shedding. The American Academy of Dermatology describes postpartum shedding as peaking around four months, with fullness tending to return within six to nine months without treatment — a natural course that makes any uncontrolled product claim in this window very hard to interpret.

Can women use finasteride for hair loss?

The finasteride label for male pattern hair loss states it is not indicated for use in women, and carries a warning that women who are or may become pregnant must not handle crushed or broken tablets because of the risk to a male fetus. Minoxidil is sold in women's formulations with their own labelling. Which treatment, if any, suits a particular kind of hair loss is a question for a dermatologist, and the trials described on this page enrolled people already diagnosed with a specific condition.